⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AIM News
AIM ImmunoTech Inc.
AiM Medical Robotics Awarded $2 Million National Cancer Institute Grant to Advance MRI-Guided Robotic Treatment of Brain Cancer
globenewswire.com
AIM
AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039
globenewswire.com
AIM
AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference
globenewswire.com
AIM
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
accessnewswire.com
AIM
AKTX
CNSP
DARE
NVNO
ERNA
GRI
MBRX
OTLK
AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ Article
globenewswire.com
AIM
Form 8-K
sec.gov
AIM
Form 8-K
sec.gov
AIM
AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic Cancer
globenewswire.com
AIM
Form 8-K
sec.gov
AIM
Form 8-K
sec.gov
AIM